Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon

Kim, Soo Ki; Kim, Soo Ryang; Imoto, Susumu; Tohyama, Madoka; Otono, Yumi; Tamura, Tomoko; Kim, Ke Ih; Kobayashi, Motoyasu; Ohtani, Aya; Sugimoto, Kumiko; Mizuguchi, Aya; Hiramatsu, Yukiko; Kudo, Masatoshi

doi:10.1159/000440633

Cited by 6 publications

(4 citation statements)

References 74 publications

(99 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to 2015 prevention guidelines, for patients who meet the criteria for antiviral therapy, the first choice of nucleos(t)ide analogs is drugs with high barrier to resistance and strong antiviral activity such as ETV and TDF [17]. In our study, patients without desire for pregnancy mostly received ETV (73.96%), whereas only 16.67% received ETV as antiviral therapy among patients with desire for pregnancy.…”

Section: Discussionmentioning

confidence: 77%

Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety

et al. 2019

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Research on effects of anti-hepatitis B virus (HBV) nucleoside analogs on male fertility and birth defects is limited and safety of nucleoside analogs in pregnancy is still a concern. Chronic hepatitis B (CHB) patients in Guangdong province were surveyed using a structured questionnaire. We collected data including medication type, fertility, and birth defects. Moreover, a survey of the knowledge of antiviral nucleoside analogs safety in fertility of male patients was conducted among physicians nationwide. Semen samples of 30 patients were collected. We screened 1050 HBV-positive male patients. Reasons for not receiving antivirals in 150 patients were “did not meet criteria for antiviral therapy,” fertility, and financial. Furthermore, 900 participants received antivirals (85.71%, 900/1050), including 792 patients with children and 15.15% (120/792) took anti-HBV treatment when preparing for pregnancy. Based on whether they received antiviral therapy during conception or not, we divided patients into two groups. In the child-bearing age group, 88.33% (106/120) of patients received telbivudine (LDT), whereas the other group mainly received entecavir (ETV) (87.20%, 586/672). No significant difference occurred in birth defect incidence rates between both groups. Furthermore, 558 physicians completed questionnaires. Reasons that influenced drug selection were “patient’s condition,” “fertility demand,” “financial condition,” and “compliance.” Telbivudine was the first-choice drug (32.80%, 183/558) while tenofovir (TDF) was the second (2.69%, 15/558). Additionally, 61.47% of physicians considered telbivudine or tenofovir as the first choice for male patients who met antiviral criteria, whereas 19% suggested delayed therapy and follow-up until childbirth. No significant changes occurred in semen volume, concentration, mobility, and percentage before and after administration of anti-HBV nucleoside analogs, which did not affect male fertility and birth defect incidence while the desire for pregnancy influenced drug selection and timing of administration. Further research on the effects of analogs on male fertility and fetal safety is required.

show abstract

Section: Discussionmentioning

confidence: 77%

Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety

et al. 2019

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…The current approved medications for HBV treatment include interferon-α (IFNα) and nucleotide analogs (NAs), including LVD, entecavir (ETV), tenofovir disoproxil fumarate, adefovir-dipivoxil (ADV), and telbivudine. [ 34 ] Various potential clinical problems are associated with the use of IFN, including the method of administration, potential severe side effects for certain subgroups of Asian patients, and limited applicability. [ 9 ] In this study, none of the HCC patients who underwent curative treatment received IFN therapy.…”

Section: Discussionmentioning

confidence: 99%

Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy

Rui

Yan²,

Zhang³

et al. 2017

Medicine

View full text Add to dashboard Cite

Liver resection may be beneficial in intermediate-stage hepatocellular carcinoma (HCC), though the benefit of postoperative anti-hepatitis B virus (HBV) therapy in these patients remains unclear. In this study, we sought to evaluate the efficacy of postoperative anti-HBV for intermediate-stage HCC patients who underwent radical liver resection.According to inclusion and exclusion criteria, this study enrolled 202 HCC patients who underwent liver resection and had a high HBV-DNA load. The patients were divided into 2 groups on the basis of postoperative anti-HBV therapy: group A included patients undergoing postoperative anti-HBV therapy, whereas group B patients did not receive any postoperative anti-HBV therapy. Factors including baseline demographics, tumor characteristics, overall long-term survival, tumor-free survival, and tumor recurrence rate were compared between the 2 groups. Moreover, univariate and multivariate analyses were used to identify risk factors of HCC recurrence.Baseline demographics and tumor characteristics were comparable between the groups. The 1-, 3-, and 5-year overall survival rates in group A were 91.3%, 80.9%, and 66.1%, respectively, values that were significantly increased compared with group B (91.7%, 60.7%, and 52.4%, respectively, P = .019). Group A patients also exhibited enhanced 1-, 3-, and 5-year tumor-free survival compared with group B patients (87.0%, 67.0%, and 62.6%, respectively, in group A; 82.1%, 50.0%, and 42.9% in group B, P = .002). In addition, the tumor recurrence rate in group B was significantly increased compared with group A (P < .01). Univariate and multivariate analyses indicated lack of postoperative anti-HBV therapy [hazard ratio (HR) = 0.882; 95% confidence interval (CI), 0.712–0.938; P = .042] to be a predictor of tumor recurrence.For intermediate-stage [Barcelona Clinic Liver Cancer (BCLC) stage B] HCC with a high HBV-DNA load, postoperative anti-HBV therapy after curative resection should be routine adjuvant therapy.

show abstract

“…The FDA has approved two drugs to treat HBV infection; however, both show poor efficacy and various side effects [20,21].…”

Section: Discussionmentioning

confidence: 99%

Anti-hepatitis B viral activity of <i>Phyllanthus niruri</i> L (Phyllanthaceae) in HepG2/C3A and SK-HEP-1 cells

Li¹,

Li²,

Wang³

et al. 2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon

Cited by 6 publications

References 74 publications

Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety

Real-Life State of Anti-Hepatitis B Virus Drug Choice in Child-Bearing Age Male Patients and Effect on Fertility and Fetal Safety

Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy

Anti-hepatitis B viral activity of <i>Phyllanthus niruri</i> L (Phyllanthaceae) in HepG2/C3A and SK-HEP-1 cells

Contact Info

Product

Resources

About